Treatment of a malignant pheochromocytoma in a dog using 131I metaiodobenzylguanidine

David A. Bommarito, Jimmy C. Lattimer, Kimberly A. Selting, Carolyn J. Henry, Michele Cohen, Gayle C. Johnson

Research output: Contribution to journalArticlepeer-review

Abstract

A 12 yr old castrated male Yorkshire terrier was presented with a history of an inoperable pheochromocytoma. Physical examination revealed a large, midabdominal mass. Neurologic examination was normal at presentation. An abdominal computed tomography scan revealed a 215 cm3 mass in the region of the right kidney. Forty-eight hours after IV injection of 370 megabecquerels (MBq, equivalent to10 millicuries [mCi]) of metaiodobenzylguanidine labeled with radioactive iodine ([131I]MIBG), standard planar scintigraphy was performed. A diffuse area of moderate uptake was noted in the midabdominal region. The dog experienced stable disease for 1.5 mo after injection based on a follow-up computed tomography (CT) scan; however, 5 mo after injection, repeat CT imaging revealed progression of the tumor, and a second IV injection of 370 MBq (10 mCi) of [131I]MIBG was administered. The dog died 3 wk after the second injection as a result of gastrointestinal blood loss that was believed to be caused by compression-induced bowel ischemia by the mass. A full necropsy was not performed, but the mass was removed for histologic evaluation, which confirmed the diagnosis of pheochromocytoma. This report is the first to document the treatment of canine pheochromocytoma using [131I]MIBG.

Original languageEnglish (US)
Pages (from-to)e188-e194
JournalJournal of the American Animal Hospital Association
Volume47
Issue number6
DOIs
StatePublished - Nov 2011
Externally publishedYes

ASJC Scopus subject areas

  • Small Animals

Fingerprint

Dive into the research topics of 'Treatment of a malignant pheochromocytoma in a dog using <sup>131</sup>I metaiodobenzylguanidine'. Together they form a unique fingerprint.

Cite this